Alternatives to the Use of Animals in Drug Research

Alternatives to the Use of Animals in Drug Research

1. Definition, rationale & scope

• Alternatives to animal experimentation are scientific methods, strategies and tools that replace, reduce or refine the use of live vertebrate animals in drug discovery, development and toxicity testing while still meeting the regulatory standards of efficacy and safety evidence (Medhi 1e Ch.1, pp.3–4, 39–40).
• Driving rationale is two-fold — ethical ("each animal has the right to life and humans should not take such a right away from them") and scientific/economic (animal models are imperfect predictors of human response; alternatives are faster, cheaper, higher-throughput) (Medhi 1e Ch.1, pp.39–40; SK Gupta Ch.1, pp.1–2).
• Allegation that scientists must answer: that new drugs can now be developed "in the test-tube or even by computer (in silico) or by microdosing directly to healthy volunteers" to assess PK/PD/toxicology — i.e. that animals are not strictly necessary (Medhi 1e Ch.1, p.39).
• The discipline is grounded in the 3Rs framework (Replacement, Reduction, Refinement), first articulated by W.M.S. Russell and R.L. Burch in The Principles of Humane Experimental Technique (1959) — cited within the Medhi chapter bibliography as the foundational 3R reference (Russell & Burch 3R principle; Medhi 1e Ch.1, suggested reading p.41).
• Scope of "alternatives" spans the whole drug-development pipeline:
  • Stage I (hit/lead discovery) — in silico virtual screening, high-throughput screening (HTS/uHTS), cell-free and cell-based assays (SK Gupta Ch.1, pp.1–2; Ch.2, pp.20–21).
  • Stage II (preclinical) — in vitro ADME/Tox (CaCo-2 permeation, PAMPA, liver microsomes, isolated hepatocytes) reduce/replace whole-animal PK and toxicity studies (SK Gupta Ch.2, pp.31–33).
  • Stage III (clinical) — human microdosing / Phase 0 reduces reliance on animal extrapolation for first-in-human dose (Medhi 1e Ch.1, p.39).
• ⚠ Conceptual boundary: animal models are not abolished — research animal use can be minimized but not entirely stopped; alternatives are mandatory where a validated replacement exists, otherwise refinement/reduction apply (Medhi 1e Ch.1, p.40).